Table 5.
Parameter | Groups | 2-Year RFS (%) | 5-Year RFS (%) | 10-Year RFS (%) | χ2 Test-Value | p-value |
---|---|---|---|---|---|---|
Age | 19–49 | 72 | 72 | 62 | 2.280 | 0.516 |
50–61 | 78 | 66 | 22 | |||
62–70 | 64 | 45 | 29 | |||
71–88 | 69 | 51 | 51 | |||
Gender | Female | 69 | 53 | 45 | 1.105 | 0.269 |
Male | 69 | 66 | 47 | |||
WHO | 0 | 88 | 85 | 75 | 17.941 | <0.001 |
1 | 58 | 45 | 31 | |||
2 | 43 | 21 | 0 | |||
3 | 0 | 0 | 0 | |||
Location | Parotid | 67 | 61 | 40 | 0.789 | 0.430 |
Submandibular | 73 | 60 | 50 | |||
Clinical nerve palsy | Yes | 53 | 50 | 23 | 2.592 | 0.009 |
No | 75 | 64 | 52 | |||
Radicality | R0 | 70 | 60 | 45 | 0.669 | 0.715 |
R1 | 69 | 45 | 43 | |||
R2 | 68 | 68 | 34 | |||
Nerve palsy after surgery | Yes | 45 | 40 | 24 | 2.995 | 0.003 |
No | 78 | 55 | 52 | |||
Histopathological type | Squamous | 55 | 46 | 0 | 6.525 | 0.258 |
Adenocarcinoma | 64 | 64 | 43 | |||
Cystic adenoid carcinoma | 76 | 59 | 59 | |||
Undifferentiated | 64 | 64 | 43 | |||
Acinic | 78 | 43 | 67 | |||
Other | 83 | 73 | 73 | |||
Neuroinvasion | Yes | 55 | 50 | 27 | 2.268 | 0.023 |
No | 76 | 63 | 55 | |||
Angioinvasion | Yes | 66 | 56 | 56 | 0.701 | 0.482 |
No | 70 | 63 | 43 | |||
Stage | I | 100 | 88 | 88 | 17.724 | <0.001 |
II | 80 | 75 | 56 | |||
III | 70 | 65 | 39 | |||
IVab | 67 | 34 | 23 | |||
T | 1 | 95 | 83 | 83 | 20.922 | <0.001 |
2 | 77 | 73 | 61 | |||
3 | 64 | 53 | 31 | |||
4 | 43 | 50 | 0 | |||
N | Positive | 46 | 36 | 24 | 3.117 | 0.002 |
Negative | 81 | 70 | 53 | |||
Time | <9 weeks | 73 | 62 | 56 | 0.949 | 0.343 |
≥9 weeks | 65 | 57 | 29 | |||
Technique of RT | 2D | 44 | 30 | 30 | 4.928 | 0.085 |
3D | 70 | 70 | 46 | |||
IMRT | 76 | 60 | 45 | |||
Dose | <60Gy | 44 | 28 | 14 | 3.489 | <0.001 |
≥60Gy | 78 | 67 | 52 | |||
CHT | Yes | 56 | 48 | 48 | 0.991 | 0.321 |
No | 71 | 62 | 44 | |||
Hemoglobin level | <12.5 mg/dL | 43 | 43 | N/A | 1.212 | 0.225 |
≥12.5 mg/dL | 68 | 56 | N/A | |||
Tumor volume | ≤10 cm3 | 95 | 83 | 83 | 9.956 | 0.019 |
10.1–50 cm3 | 76 | 71 | N/A | |||
50.1–100 cm3 | 70 | 56 | 0 | |||
>100 cm3 | 44 | 44 | N/A | |||
Irradiation area | Only surgical bed with margin | 83 | 68 | 55 | 13.555 | 0.004 |
Surgical bed + lnd. group I-II | 76 | 71 | N/A | |||
Surgical bed + unilateral lnd. | 74 | 70 | 42 | |||
Surgical bed + bilateral lnd | 38 | 19 | 19 | |||
Tumor bed volume (dose ≥ 60Gy) | ≤100 cm3 | 93 | 93 | 78 | 6.204 | 0.102 |
100.1–200 cm3 | 80 | 72 | N/A | |||
200.1–300 cm3 | 67 | 59 | N/A | |||
>300 cm3 | 50 | 50 | 0 | |||
Elective area volume (dose ≥ 50Gy) | ≤ 150 cm3 | 88 | 85 | 56 | 7.205 | 0.125 |
150.1–300 cm3 | 70 | 52 | N/A | |||
300.1–450 cm3 | 60 | N/A | N/A | |||
450.1–600 cm3 | 58 | 58 | 0 | |||
>600 cm3 | 33 | 33 | N/A |
Note: Statistically significant results in bold.
Abbreviations: p, significance level; R0, radical surgery; R1, non-radical microscopic surgery; R2, non-radical macroscopic surgery; RT, radiotherapy; CHT, chemotherapy; RT, radiotherapy; 2D, two-dimensional planning; 3D, three-dimensional planning; IMRT, planning with intensity-modulated radiation therapy.